BVX - Bovie Medical Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
5.56
-0.23 (-3.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.79
Open5.74
Bid0.00 x 1300
Ask0.00 x 3000
Day's Range5.56 - 5.82
52 Week Range2.28 - 7.62
Volume58,573
Avg. Volume190,275
Market Cap184.611M
Beta (3Y Monthly)-2.14
PE Ratio (TTM)N/A
EPS (TTM)-0.11
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.88
Trade prices are not sourced from all markets
  • Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition
    Zacks3 days ago

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

  • Snap Up These 5 Stocks on New Analyst Coverage
    Zacks6 days ago

    Snap Up These 5 Stocks on New Analyst Coverage

    Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

  • Simply Wall St.8 days ago

    Are Bovie Medical Corporation’s (NYSEMKT:BVX) Interest Costs Too High?

    While small-cap stocks, such as Bovie Medical Corporation (NYSEMKT:BVX) with its market cap of US$213m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Implied Volatility Surging for Bovie Medical (BVX) Stock Options
    Zacks10 days ago

    Implied Volatility Surging for Bovie Medical (BVX) Stock Options

    Bovie Medical (BVX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?
    Zacks10 days ago

    Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?

    Investors need to pay close attention to Bovie Medical (BVX) stock based on the movements in the options market lately.

  • Business Wire14 days ago

    Bovie Medical Corporation to Release Third Quarter of Fiscal Year 2018 Financial Results on November 1, 2018

    Bovie Medical (BVX), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the third quarter of fiscal year 2018 will be released after the market closes on Thursday, November 1. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 6375776. Participants should ask for the Bovie Medical Corporation Call.

  • Business Wirelast month

    Bovie Medical Corporation to Present at the Sidoti & Company Fall 2018 Investor Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the Sidoti & Company Fall 2018 Investor Conference at the Grand Hyatt in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/.

  • Business Wirelast month

    Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today updated financial guidance expectations for the twelve months ending December 31, 2018. The Company is introducing fiscal year 2018 financial guidance on a continuing operations basis as adjusted, which reflects the consummation of the Core segment sale transaction which closed on August 30, 2018. Total revenue from continuing operations in the range of $15.2 million to $15.6 million, representing growth of 49% to 53% year-over-year, compared to total revenue from continuing operations of $10.2 million in fiscal year 2017.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Completion of “Core” Business Segment Sale to Symmetry Surgical, Inc. for Total Cash Consideration of $97 Million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that it has completed the previously announced divestiture and sale of the Core business segment and the Bovie® brand to Symmetry Surgical, Inc. for gross proceeds of $97 million in cash. Bovie Medical shareholders voted to approve the divestiture and sale transaction at an annual meeting of shareholders held on August 30, 2018.

  • Associated Press3 months ago

    Bovie: 2Q Earnings Snapshot

    On a per-share basis, the Clearwater, Florida-based company said it had a loss of 1 cent. The medical device maker posted revenue of $11.5 million in the period. In the final minutes of trading on Wednesday, ...

  • Business Wire3 months ago

    Bovie Medical Corporation Reports Second Quarter 2018 Financial Results

    Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year

  • Business Wire3 months ago

    Bovie Medical Corporation to Release Second Quarter of Fiscal Year 2018 Financial Results on August 1, 2018

    Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the second quarter of fiscal year 2018 will be released after the market closes on Wednesday, August 1. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • Business Wire3 months ago

    Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that the Company has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions – including approval by the Company’s stockholders – and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

  • Business Wire3 months ago

    Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced preliminary revenue results for the second quarter of fiscal year 2018.

  • Business Wire5 months ago

    Bovie Medical Corporation to Participate in the JMP Securities 2018 Life Science Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the JMP Securities 2018 Life Science Conference at the St. Regis New York in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • ACCESSWIRE5 months ago

    Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.

  • ACCESSWIRE5 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...

  • Associated Press5 months ago

    Bovie: 1Q Earnings Snapshot

    The Clearwater, Florida-based company said it had a loss of 3 cents per share. The medical device maker posted revenue of $9.9 million in the period. Bovie expects full-year revenue in the range of $41 ...

  • Business Wire5 months ago

    Bovie Medical Corporation Reports First Quarter 2018 Financial Results; Reaffirms Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2018.

  • Business Wire5 months ago

    Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing. “We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • ACCESSWIRE5 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Bovie Medical Corporation (NYSE American: BVX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Appointment of Diane I. Duncan, M.D., FACS to Medical Advisory Board

    Bovie Medical Corporation (BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Diane I. Duncan, M.D., FACS to the Company’s Medical Advisory Board. “Dr. Duncan joins our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire6 months ago

    Bovie Medical Corporation to Release First Quarter of Fiscal Year 2018 Financial Results on May 14, 2018

    Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of fiscal year 2018 will be released after the market closes on Monday, May 14.